To provide a therapeutic agent, a therapeutic composition and kit production of retrovirus infection.
A use of a therapeutically effective amount of 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (hereinafter referred to as a compound I) or a pharmaceutically acceptable salt thereof is provided. Further, the use of the compound I or the salt thereof for an inhibitor of integrase activity is provided. The compound I or the salt thereof is also effective in inhibiting replication of a retrovirus resistant to at least one anti-retroviral drug. The compound I or the salt thereof is administered alone or in combination with at least one anti-retroviral drug other than the compound I or the salt thereof. Further, production of a kit containing the compound I or the salt thereof is provided.
KANO MITSUKI
IKEDA SATORU
JP2006001927A | 2006-01-05 |
WO2004046115A1 | 2004-06-03 | |||
WO1999048371A1 | 1999-09-30 | |||
WO2005112930A1 | 2005-12-01 |
JPN7010000484; 医学のあゆみ vol.213, no.10, 2005, p.891-900
JPN7010000485; ANTIVIRAL RESEARCH vol.46, no.3, 2000, p.223-232
JPN7010000486; 現代医療 vol.34, no.5, 2002, p.1135-1141
Kyoko Doi
Mitsunori Kamata
Yaeko Tamura
Kenji Yamamoto
Murata Miyuki
Next Patent: IMIDAZOLOTHIAZOLE COMPOUND FOR TREATING DISEASE